| Literature DB >> 32567021 |
Ran Li1, Xing Wan2, Timo M Takala2, Per E J Saris2.
Abstract
The yeast Saccharomyces boulardii is well known for its probiotic effects such as treating or preventing gastrointestinal diseases. Due to its ability to survive in stomach and intestine, S. boulardii could be applied as a vehicle for producing and delivering bioactive substances of interest to human gut. In this study, we cloned the gene lecC encoding the antilisterial peptide leucocin C from lactic acid bacterium Leuconostoc carnosum in S. boulardii. The constructed S. boulardii strain secreted a peptide, which had molecular weight corresponding to leucocin C in SDS-PAGE. The peptide band inhibited Listeria monocytogenes in gel overlay assay. Likewise, concentrated S. boulardii culture supernatant inhibited the growth of L. monocytogenes. The growth profile and acid tolerance of the leucocin C secreting S. boulardii were similar as those of the strain carrying the empty vector. We further demonstrated that the cells of the leucocin C producing S. boulardii efficiently killed L. monocytogenes, also without antibiotic selection pressure. These results showed that antilisterial activity could be added to the arsenal of probiotic activities of S. boulardii, demonstrating its potential as a carrier for therapeutics delivery.Entities:
Keywords: Bacteriocin; Heterologous expression; Leucocin C; Probiotic yeast; Saccharomyces boulardii
Mesh:
Substances:
Year: 2021 PMID: 32567021 PMCID: PMC7904741 DOI: 10.1007/s12602-020-09676-1
Source DB: PubMed Journal: Probiotics Antimicrob Proteins ISSN: 1867-1306 Impact factor: 4.609